We are live on ! Find out more

CTNM

Contineum Therapeutics

CTNM

Market cap $558M

14.82 USD

0.00

0%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

14.30

-0.52

3.51%

1 day

0%

5 days

-10.67%

1 month

4.44%

3 months

16.51%

6 months

10.85%

Year to date

30.11%

1 year

19.61%

5 years

-3.77%

10 years

-3.77%

About: Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Employees: 51

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 66.7%

Negative 16.7%

Contineum, J&J's depression drug fails to meet mid-stage trial goal

Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal ‌of a mid-stage study.

Contineum, J&J's depression drug fails to meet mid-stage trial goal

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo.

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of.

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones. “We continue to expand our footprint for PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients.

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid R.

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Co.

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

Zacks Investment Research

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stoc.

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™